Elisabeth Puchhammer-Stöckl
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 2 | 2021 | 52 | 1.58 | Why? |
| Lung Transplantation | 3 | 2018 | 1554 | 0.96 | Why? |
| Torque teno virus | 2 | 2018 | 73 | 0.88 | Why? |
| Antigens, Differentiation, T-Lymphocyte | 1 | 2019 | 146 | 0.76 | Why? |
| Cytomegalovirus Infections | 2 | 2018 | 667 | 0.70 | Why? |
| Orthomyxoviridae | 2 | 2021 | 1168 | 0.54 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.42 | Why? |
| Recombinant Proteins | 1 | 2020 | 3786 | 0.40 | Why? |
| DNA, Viral | 4 | 2020 | 2521 | 0.40 | Why? |
| Plasma | 1 | 2018 | 1809 | 0.35 | Why? |
| Austria | 6 | 2021 | 1259 | 0.35 | Why? |
| Graft Rejection | 1 | 2018 | 1766 | 0.35 | Why? |
| Genetic Predisposition to Disease | 2 | 2019 | 4027 | 0.32 | Why? |
| Cytomegalovirus | 2 | 2017 | 600 | 0.31 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2019 | 3607 | 0.31 | Why? |
| Drug Resistance, Viral | 3 | 2015 | 1083 | 0.23 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.20 | Why? |
| Respiratory Tract Infections | 1 | 2021 | 6817 | 0.20 | Why? |
| Laboratory Proficiency Testing | 1 | 2020 | 85 | 0.20 | Why? |
| HLA-A Antigens | 1 | 2021 | 196 | 0.19 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.19 | Why? |
| Mutation | 6 | 2021 | 12376 | 0.18 | Why? |
| Codon, Terminator | 1 | 2018 | 72 | 0.18 | Why? |
| Metapneumovirus | 1 | 2021 | 465 | 0.18 | Why? |
| Influenza, Human | 2 | 2021 | 10779 | 0.18 | Why? |
| Histocompatibility Antigens Class II | 1 | 2021 | 383 | 0.18 | Why? |
| Hepatitis B Surface Antigens | 1 | 2018 | 305 | 0.16 | Why? |
| Quality Assurance, Health Care | 1 | 2021 | 596 | 0.15 | Why? |
| Metagenome | 1 | 2018 | 268 | 0.15 | Why? |
| Candidemia | 1 | 2020 | 353 | 0.15 | Why? |
| Rhinovirus | 1 | 2021 | 979 | 0.14 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 7868 | 0.14 | Why? |
| Immunoassay | 2 | 2021 | 4485 | 0.14 | Why? |
| Biodiversity | 1 | 2018 | 546 | 0.14 | Why? |
| Angiotensin II | 1 | 2020 | 601 | 0.14 | Why? |
| Gene Frequency | 1 | 2019 | 1210 | 0.14 | Why? |
| Respiratory Syncytial Virus, Human | 1 | 2021 | 846 | 0.13 | Why? |
| Sequence Deletion | 1 | 2018 | 674 | 0.13 | Why? |
| Alleles | 1 | 2019 | 1557 | 0.13 | Why? |
| HIV-1 | 3 | 2015 | 3365 | 0.13 | Why? |
| Anti-HIV Agents | 3 | 2015 | 2209 | 0.13 | Why? |
| Polymerase Chain Reaction | 3 | 2020 | 6740 | 0.12 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.12 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.12 | Why? |
| Metagenomics | 1 | 2018 | 823 | 0.12 | Why? |
| Biomarkers | 3 | 2020 | 23361 | 0.11 | Why? |
| Hepatitis B, Chronic | 1 | 2018 | 616 | 0.11 | Why? |
| Hepatitis B virus | 1 | 2018 | 882 | 0.11 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2021 | 2262 | 0.10 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.10 | Why? |
| Killer Cells, Natural | 1 | 2019 | 2093 | 0.10 | Why? |
| Lung | 1 | 2018 | 31049 | 0.10 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 2309 | 0.10 | Why? |
| Blood | 1 | 2010 | 274 | 0.09 | Why? |
| Genome, Viral | 2 | 2021 | 13157 | 0.09 | Why? |
| Seasons | 1 | 2021 | 4071 | 0.09 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.09 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.08 | Why? |
| Molecular Diagnostic Techniques | 2 | 2021 | 4239 | 0.08 | Why? |
| Public Health Surveillance | 1 | 2021 | 3129 | 0.08 | Why? |
| Humans | 26 | 2021 | 930598 | 0.08 | Why? |
| Outpatients | 1 | 2019 | 3417 | 0.08 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2021 | 13720 | 0.08 | Why? |
| Genotype | 3 | 2018 | 4697 | 0.08 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.08 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.07 | Why? |
| Female | 14 | 2021 | 380317 | 0.07 | Why? |
| Amino Acid Substitution | 2 | 2018 | 1706 | 0.07 | Why? |
| Adult | 11 | 2021 | 244371 | 0.07 | Why? |
| Phylogeny | 3 | 2020 | 13341 | 0.07 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.07 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.07 | Why? |
| Male | 13 | 2021 | 367725 | 0.07 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.06 | Why? |
| Sequence Analysis, DNA | 2 | 2010 | 2830 | 0.06 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 2426 | 0.06 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.06 | Why? |
| Virus Diseases | 1 | 2021 | 3779 | 0.06 | Why? |
| Sensitivity and Specificity | 5 | 2021 | 22971 | 0.06 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.06 | Why? |
| Transplant Recipients | 1 | 2018 | 4982 | 0.06 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.06 | Why? |
| Viral Load | 2 | 2018 | 15850 | 0.05 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.05 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.05 | Why? |
| Reverse Transcriptase Inhibitors | 2 | 2015 | 309 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| HIV Infections | 2 | 2015 | 11620 | 0.05 | Why? |
| Immunoglobulin A | 2 | 2021 | 3567 | 0.05 | Why? |
| Aged | 7 | 2021 | 215776 | 0.05 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.05 | Why? |
| Mutation Rate | 1 | 2020 | 382 | 0.04 | Why? |
| HIV Protease Inhibitors | 2 | 2015 | 434 | 0.04 | Why? |
| Infant, Newborn | 1 | 2019 | 23105 | 0.04 | Why? |
| Viral Envelope Proteins | 1 | 2010 | 3539 | 0.04 | Why? |
| Quality Control | 1 | 2021 | 628 | 0.04 | Why? |
| DNA Virus Infections | 1 | 2017 | 88 | 0.04 | Why? |
| Infant | 1 | 2019 | 30274 | 0.04 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.04 | Why? |
| False Positive Reactions | 1 | 2020 | 1338 | 0.04 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.04 | Why? |
| Child, Preschool | 1 | 2019 | 36283 | 0.04 | Why? |
| Europe | 3 | 2018 | 12702 | 0.04 | Why? |
| Transplantation, Homologous | 1 | 2017 | 757 | 0.03 | Why? |
| Herpesvirus 4, Human | 1 | 2017 | 387 | 0.03 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.03 | Why? |
| Diagnostic Errors | 1 | 2020 | 865 | 0.03 | Why? |
| Child | 2 | 2021 | 70012 | 0.03 | Why? |
| Cell Proliferation | 1 | 2021 | 1973 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| Erythema Infectiosum | 1 | 1992 | 31 | 0.03 | Why? |
| Base Sequence | 1 | 2020 | 3581 | 0.03 | Why? |
| Agranulocytosis | 1 | 1992 | 65 | 0.03 | Why? |
| Nasopharynx | 2 | 2020 | 10224 | 0.03 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Antifungal Agents | 1 | 2020 | 1828 | 0.02 | Why? |
| Epitopes | 1 | 2021 | 4113 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3633 | 0.02 | Why? |
| Peptides | 1 | 2021 | 2513 | 0.02 | Why? |
| Laboratories | 1 | 2021 | 2858 | 0.02 | Why? |
| Hospitalization | 1 | 2019 | 54280 | 0.02 | Why? |
| Genes, pol | 1 | 2006 | 38 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2015 | 2886 | 0.02 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.02 | Why? |
| HIV Reverse Transcriptase | 1 | 2006 | 104 | 0.02 | Why? |
| HIV Protease | 1 | 2006 | 86 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2017 | 4758 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Antiviral Agents | 1 | 2018 | 41703 | 0.02 | Why? |
| Codon | 1 | 2006 | 287 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.02 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.02 | Why? |
| Prevalence | 2 | 2015 | 25773 | 0.02 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.01 | Why? |
| Geography | 1 | 2006 | 1801 | 0.01 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| Evolution, Molecular | 1 | 2006 | 3691 | 0.01 | Why? |
| Cell Count | 1 | 1992 | 228 | 0.01 | Why? |
| Hematopoiesis | 1 | 1992 | 168 | 0.01 | Why? |
| Granulocytes | 1 | 1992 | 140 | 0.01 | Why? |
| Bone Marrow | 1 | 1992 | 492 | 0.01 | Why? |
| Recurrence | 1 | 1992 | 3675 | 0.00 | Why? |
| RNA, Viral | 1 | 2006 | 32276 | 0.00 | Why? |